Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 421-430 of 2904 for cancer

Edit search filters
  1. Methotrexate, Erlotinib, And Celecoxib For The Treatment Of Recurrent/Metastatic Oral Cavity Cancer In A Rural Midwest United States Population

    Albert Lea, MN, La Crosse, WI, Rochester, MN

  2. A Study to Reduce Cardiomyopathy in Breast Cancer Patients Being Treated With Trastuzumab

    Rochester, MN

  3. Study Of NMS-03597812 In Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Rochester, MN

  4. A Study Of Neoadjuvant/Adjuvant Durvalumab For The Treatment Of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

    Scottsdale/Phoenix, AZ

  5. Vaccine Therapy and Resiquimod in Treating Patients with Stage II-IV Melanoma that has been Removed by Surgery

    Rochester, MN

  6. A Mindfulness-Based Stress Reduction Program For Improving Mental Health Outcomes For Underserved Cancer Patients In Minnesota

    Rochester, MN

  7. A Study Of A Selective ERBB2 Inhibitor (CGT4255), In Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. Lead-212 PSV359 Therapy For Patients With Solid Tumors

    Rochester, MN

  9. (Neo)Adjuvant IDE196 (Darovasertib) In Patients With Localized Ocular Melanoma

    Rochester, MN

  10. A First-in-Human (FIH) Study To Evaluate The Safety And Tolerability Of VVD-159642 In Participants With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer